To gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC-associated gene, HCCA1 encoding a *80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event frequently (89.2%) in HCCs and correlated significantly with the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH-7) was effectively suppressed and cell growth was down-regulated in a time-and dose-dependent manner. Furthermore, HuH-7 cells harboring the HCCA1 antisense expression clone displayed a remarkably reduced efficiency in colony formation. Together, these data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.
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Introduction
Human primary hepatocellular carcinoma (HCC), one of the most common malignancies of the liver, is prevalent in South-East Asia and Sub-Saharan Africa, where it is associated with environmental exposure to hepatitis B virus, hepatitis C virus, and Aflatoxin B1, and it is rising in incidence throughout the world with the spread of hepatitis B and C (Schafer and Sorrell, 1999; Ince and Wands, 1999) . HCC carries a very poor prognosis, and the 5-year survival rate is limited to 25 -39% after surgery (Colombo, 1992) . The obstacles for cure of this disease are primarily attributable to the highly post-operational recurrence and metastasis. Pathologically, HCC occurs largely on chronically diseased liver mainly caused by hepatitis viral infections. The long period of chronic liver lesion, inflammation and liver cell turnover often result in cirrhosis and finally carcinoma (Ferrell, 2000; Ponder, 1996) . The multiple hepatocarcinogenesis involves large molecular events including genetic and epigenetic changes, which accumulate through progression (Hui and Makuuchi, 1999; Zimmermann et al., 1997) . The genetic deviation encompasses DNA rearrangements associated with viral genome integration (Zondervan et al., 2000) , point mutations (Ogata et al., 1991; Shimizu et al., 1999; de La Coste et al., 1998) , loss of heterozygosity (Teeguarden et al., 2000; Kondo et al., 2000) , chromosomal amplifications (Kawate et al., 1999) , changes in methylation (Kondo et al., 2000; Shen et al., 1998) , translocations (Keck et al., 1999) , and gain or loss of imprinting (de Souza et al., 1997; Schwienbacher et al., 2000) . These changes could occur in a variety of cellular genes leading to escape from normal cellular and environmental controls. So far, over 20 cellular genes down-or up-regulated or mutated in HCC such as ras (Ogata et al., 1991; Kim et al., 2001) , c-myc, c-fos, and c-jun (Kawate et al., 1999; Yuen, et al., 2001) , rho (Genda et al., 1999) , TGFa (Chung et al., 2000) , HGF and c-met (Ueki et al., 1997) , c-erbB-2 (Collier et al., 1992) , IGF-II (Takeda et al., 1996) , u-PA (de Petro et al., 1998) , MXR7 (Hsu et al., 1997) , MDM2 (Endo et al., 2000) , MAGE (Tahara et al., 1999) , matrix metalloproteinase (Musso et al., 1997) , Smads (Yakicier et al., 1999) , p53 (Shimizu et al., 1999; Rashid et al., 1999) , pRB Santoni-Rugiu et al., 1998) , p16INK4 Liew et al., 1999) , p21 WAF1/CIP1 , p27 Kip1 (Chen et al., 2000; Tannapfel et al., 2000) , PTEN (Fujiwara et al., 2000; Yao et al., 1999) , E-cadherin ), beta-catenin (de La Coste et al., 1998 and AXIN1 (Satoh et al., 2000) have been described in humans and mice. Many of them are involved in deregulation of intracellular signal transduction and cell cycle, leading eventually to an uncontrolled proliferation of cancerous cells. The genetic abnormalities are accumulative and they cooperatively contribute to tumor progression. However, these findings are, in most cases, also observed in many other types of cancer. More critical molecules specific for HCC, which will be more informative, remain to be elucidated. In this study, we employed a differential display method (Liang et al., 1993) to analyse altered gene expression patterns between HCC tissues and their nontumorous counterparts and isolated a novel gene that is up-regulated selectively by HCC, termed HCCA1 (hepatocellular carcinoma associated gene 1). HCCA1 transcript is highly expressed in about 90% of HCCs and is clinicopathologically correlated with the extent of HCC progression. HCCA1 cDNA encodes a cytoplasmic protein that contains several putative proline-rich motifs and it is anticipated to work through interaction with SH3-containing proteins in eukaryotic signal transduction, or directing cell compartmentalization (Kay et al., 2000) .
Results

DD -PCR assay, cDNA cloning and amino acid sequence analysis
We established gene expression profiles through DD -PCR analysis (Liang et al., 1993) to discriminate genes that were differentially expressed between HCC and nontumorous liver tissues. The assay was initially performed on HCC and the adjacent liver RNA samples were isolated from two patients with HCC, and one normal liver RNA sample served as control. DD -PCR products were fractioned on sequencing gels and potentially differential transcripts were represented as bands that were displayed alternatively in either HCC or adjacent liver tissue samples. Collectively, the extensive DD -PCR analysis resulted in the isolation of more than 100 differential cDNA fragments, strongly supporting that this technique is powerful for screening HCC-related genes. This paper is focusing on the identification of a highly expressed gene in HCC as described below. From the fractioned gel, a candidate cDNA fragment that is presented in both HCCs but not in their nontumorous counterparts or normal liver tissue was isolated, re-amplified, subcloned and then served as a specific probe to screen a human placental cDNA library. From this library, eight positive clones were analysed. Sequencing revealed that the overlapping clones predict a single open reading frame (ORF). No deletion or alteration of the ORF was observed. One cDNA clone of 2702 bp in length contains the complete ORF. Its putative initiator methionine is quite consistent with the Kozak consensus (Kozak, 1984) . We observed multiple stop codons in frame upstream from this methionine start codon and a single polyadenylation signal followed by a poly(A) tail at the 3'-end.
Application of 5' rapid amplification of cDNA ends did not reveal any additional sequence information. The length of the transcript was finally verified by Northern blot analysis that was performed on various adult tissues, different type of tumors including HCCs and a number of cell lines. It is demonstrated that a major hybridization band of approximately 2.7 kb corresponding to mRNA species in expressed tissues or cells fits the length of the cloned cDNA very well. Some adult tissues such as brain also have a second transcript, about 1.5 kb, which may represent either an incompletely spliced, or alternatively spliced form of the transcript. Taken together, this clone represented a full-length cDNA, which we named HCCA1 (hepatocellular carcinoma associated gene 1).
HCCA1 cDNA predicts a putative protein of 719 amino acids that has no obvious signaling sequence, transmembrane domain, or consensus for nuclear localization, suggesting that it is a cytoplasmic protein.
The deduced protein is estimated to have a molecular mass of 79.5 kDa and a pI of 8.22. It consists of 45.5% hydrophobic amino acids, 31.0% hydrophilic amino acids, 13.4% basic amino acids and 10.2% acidic amino acids. Interestingly, the putative amino acid sequence is rich in proline content (11% proline), which is significantly higher than the average proline composition (4.6% proline) in eukaryotic protein.
There are five sites containing a PXXP consensus sequence in the C-terminal region of the HCCA1 protein and two of those have a pXPXXP motif. Based on their homology to similar sequence elements, these sites are potential sites for SH3-binding (Lim et al., 1994; Yu et al., 1994) . This protein also contains numerous potential phosphorylation sites for PKC, PKA, PKG, GSK3, p34cdc2, CaMII, CK I, CK II and tyrosine kinases. A schematic presentation of the HCCA1 cDNA structure is shown in Figure 1 .
Expression in HCC tissues and clinicopathological significance
Differential display experiments allow us to clone the full-length cDNA of this highly expressed gene in HCCs. More conclusive information comes from the data that HCCA1 is expressed preferentially by HCCs as seen at mRNA level via Northern blot analysis ( Figure 2a ) and in situ hybridization ( Figure 2b ) and at protein level analysed with an immunohistochemical approach ( Figure 2c ) using a polyclonal antibody that was raised against the HCCA1 N-terminal domain containing the first 174 amino acids as described below. The specificity of anti-HCCA1 antibody in immunohistochemical detection was confirmed by competitive inhibition experiments in which we found that preabsorption of the antisera with the immunizing antigen (HCCA1-GST) abolished HCCA1 staining either in HCC or in HuH-7 cells. In contrast, preabsorption with GST protein had no effect on HCCA1 staining (data not shown). Out of 102 HCCs, 91 (89.2%) expressed high level of HCCA1 mRNA. In the adjacent livers, only 9 (8.8%) expressed very weak HCCA1 mRNA and most (91.2%) were undetectable. There were prominent statistical differences in HCCA1 mRNA levels between subgroups concerning histological grades, satellite nodules, thrombus and Ki-67 index (Figure 2d ). It was observed that HCCA1 mRNA level was higher (P50.05) in poorly differentiated HCCs (grades III-IV, n=76) when compared with well differentiated HCCs (grades I-II, n=26). We also noted a remarkably positive correlation with intrahepatic metastasis and vascular invasion. The expression level was higher (P50.01) in HCCs that had satellite tumor nodules (n=43) than in those with integrity of capsule (n=36), higher (P50.01) in HCCs that had portal vein tumor thrombus (n=28) than those without (n=74). To investigate the possible relationship between HCCA1 and Ki-67, we simply divided HCCs into two groups based on Ki-67 expression level. For this purpose, microscopy was performed by counting 41000 tumorous cells in a randomly selected highpower field (106100) from different representative parts of the tumor. Ki-67 expression level was grouped as high if 20% tumorous cells were Ki-67 positive, and as low if staining was 520% as described (King et al., 1998) . As a result, HCCA1 expression level was closely correlated with the Ki-67 index (P50.01). We observed significant up-regulation of HCCA1 mRNA in the high Ki-67 group (n=76) when compared with the low Ki-67 group (n=26). There were no significant correlations with sex, age, HBV and/or HCV infection, serum AFP level and histological situation of noncancerous liver.
Expression in various cell lines, tissue distribution and analysis among different tumors
As shown in Figure 3a ,b, HCCA1 mRNA was also strongly expressed in a number of HCC related cell lines including HepG2, HuH-7, SK-Hep-1, NCI-H1755, Ts817t, Chang liver and one human fetal hepatocyte cell line of WRL68. To look into the possible role of HCCA1 in physiological processes, normal tissues including brain, lung, skeletal muscle, spleen, heart, small and large intestine, stomach, liver and pancreas were screened for HCCA1 expression by Northern blot. The results showed that HCCA1 mRNA was expressed in some of these tissues especially in brain, lung, skeletal muscle, but not in liver, pancreas and stomach ( Figure 3c ). To check if a tumor-specific manner occurs with HCCA1, we examined the HCCA1 mRNA expression in a number of various malignant tumors derived from stomach, colon, rectum, breast and kidney. Among them, we observed that HCCA1 mRNA is expressed in colorectal cancers but at similar level between cancerous and noncancerous tissues. The other tumors do not reveal any detectable HCCA1 mRNA whatever in tumor tissues or in nontumor tissues (Figure 3d ).
Immunocharacterization of the encoded protein
To confirm that the HCCA1 cDNA clone indeed encodes a functional protein, we constructed several expression vectors and introduced into protokaryotic or eukaryotic cells to estimate the molecular weight as well as to identify the subcellular localization. We showed that the putative ORF for HCCA1 can be translated, in part or in completeness, in protokaryotic cells such as E. coli BL-21 (data not shown). For further characterization, polyclonal antibody against N-terminal domain containing the first 174 amino acids was generated. Using this antibody, we found that HEK293 cells can overexpress a *80 kDa protein when transiently transfected with the expression vector pcDNA3 containing the full-length HCCA1 cDNA, as compared with the mock control. This antibody again recognized the protein in HuH-7 cells in the same position, indicating an endogenous expression. The apparent molecular mass by SDS -PAGE was consistent with that predicted from the cDNA sequence ( Figure 4a ). Immunohistochemistry experiment showed that the HCCA1 protein was mainly localized in the cytoplasmic compartments as determined in HuH-7 cell line ( Figure 4b ) as well as in liver cancerous cells from HCC tissues as indicated above in Figure 2b .
Antiproliferative effect of antisense oligonucleotides or antisense expression clone
To examine whether or not HCCA1 might affect the growth of HCC cells, an antisense approach was employed in this study. Because the region of a cDNA that yields effective antisense RNA cannot be predicted with certainty, antisense oligonucleotides (AS) were tested from different regions of the HCCA1 cDNA. That is, AS1 is intended to represent a region encompassing the translational start site, while AS2 and AS3 are designated to two putative proline-rich regions. The corresponding sense sequences (S1 through S3) and a random 24-mer oligonuleotide (R) with a similar GC content to the specific antisense oligonucleotides were selected as controls. In these experiments, we did not observe significant cytotoxicity at dosage up to 1500 nM. Therefore, various concentrations of ODNs in this range (0, 100, 500, 1000, 1500 nM) were selected to explore the dosage-efficacy relationship. As shown in Figure 5a , antisense oligonucleotides exerted negative roles in cell growth and the effects were found to be time-and dosedependent. These antiproliferative effects directly correlated with the degree of HCCA1 mRNA reduction in HuH-7 cells by antisense oligonuleotides. We pooled the cells to examine whether antisense oligonuleotides function well in eliminating target mRNA in a sequence-specific manner. As exemplified in Figure 5b , we found that 1000 nM AS1 was able to ablate HCCA1 mRNA by 42%, while AS1 at a dosage of 1500 nM increases the inhibitory effect to 69%. AS2 and AS3 also had similar effects (data not shown). In contrast, no significant influence was observed on HCCA1 mRNA with the corresponding sense oligonucleotides. In clonogenic formation assay, we constructed antisense expression clone against the whole ORF of HCCA1 and introduced into HuH cells under selection with G418 for three weeks. Transfection efficiency as determined by cotransfection with a pCMV-bGAL vector was 25 -30%, which was approximately the same with either the antisense HCCA1 expression vector or with the control vector. As shown in Figure 5c ,d, colony formation efficiency in HCCA1 antisense expressed HuH-7 cells was reduced by 70%, as compared with the vector control. Furthermore, the individual colony size of the cells transduced with HCCA1 antisense construct was significantly decreased compared with the vector colonies. We detected that low antisense RNA expression was induced in HuH-7 cells transfected with HCCA1 antisense clone, while sense RNA level was significantly reduced in these cells (data not shown).
Discussion
HCC occurs in the context of various genetic and epigenetic changes and grows more and more malignant with the increase of altered molecules. Although a number of cellular genes have been described as involved during the HCC carcinogenesis, little is reported unique for HCC. Therefore, it is critical for HCC to seek more unknown proteins. Identification of novel HCC-related proteins will greatly improve our understanding of this disease and will encourage us to develop new targets for diagnosis and biotherapy. In the last two decades, great advances have been made in cloning methodologies. Among these, mRNA differential display (Liang et al., 1993 ) is a powerful method. Widely screening genes differentially expressed in HCC will provide us with a profile of molecules involved in detail as shown in this study, as well as by others (Kondoh et al., 1999) . In this paper, we reported the identification and characterization of a novel human HCC-associated gene, designated as HCCA1. This gene was initially identified as a candidate gene that is overexpressed in HCC tissues (HCCs) but undetectable in nontumorous or normal liver tissues as determined by a differential display experiment. It was verified in vivo that HCCA1 is expressed preferentially in HCCs but not in the adjacent liver tissues at both mRNA (by in situ hybridization) and protein (by immunohistochemistry) levels. We further confirmed that high expression of HCCA1 is frequent (89.2%) in HCCs, while only 8.8% paracarcinoma liver tissues also express very low HCCA1. The up-regulation of HCCA1 in tumors seems unique with HCC, for we did not detect significant elevation in other neoplasms such as gastric, colorectal, breast and kidney cancers.
Because the types and the number of tumors were limited, extended samples are needed to provide conclusive information. In HCC, we noted that HCCA1 expression level was higher in poorly differentiated tumors and in those with portal thrombus and satellite invasion. These clinicopathological data strongly suggest that HCCA1 is a late event in HCC and has a metastatic potential. We analysed the sequence of HCCA1 cDNA showing no significant identity with known cDNA sequences in the GenBank database, however, a search against the EST database demonstrated that it is identical to a number of homo sapiens EST clones derived from various fetal tissues of different stages of embryogenesis, including 8 to 9-week total fetus (AI039011), 19-week fetal lung (AI355167), 20-week fetal liver and spleen (AI168334), fetal heart (W67202), fetal thymus (AW026969) and germinal center B cells (AW402568), implying that HCCA1 cDNA may encode a fetal protein possibly involved in the regulation of embryonic development. In our study, we demonstrated that HCCA1 is highly expressed in one cell line (WRL 68) derived from human fetal liver at both mRNA and protein (data not shown) levels, which may somewhat support this hypothesis. However, direct evidence for HCCA1 in embryogenesis needs performance on fetal tissues. It is generally believed that a fetal protein, highly expressed at fetal stages and quickly shut down after birth, could reoccur at tumor stages. Such molecules are most likely to be a tumor marker and might act as an oncogenic protein involved in carcinogenesis (Duffy, 2001; Johnson, 2001) . HCCA1 cDNA contains an ORF encoding a protein of 719 amino acids. Our experiments confirmed that this ORF can be translated into a *80 kDa protein in protokaryotic or eukaryotic cells and revealed a subcellular localization in cytoplasmic compartment. When thoroughly checked against the GenBank database, this protein revealed no significant homology with known proteins. The informative structure feature is the PXXP consensus sequences that repeat several times at the C-terminal end. This resembles many other known SH3 domain ligands, which often exhibit multiple proline-rich motifs. The proline-rich motifs could direct interaction with multiple SH3 domains through the involvement of different residues flanking the proline-rich core, or by binding to SH3 domains in alternate orientations (Lim et al., 1994) . Analysis of these structures showed that two HCCA1 sites containing pXPXXP motifs are flanked by hydrophobic or positively charged residues, which may be the most likely binding sites for SH3 domains (Yu et al., 1994) . These motifs are widely known to play a role in mediating protein-protein interactions involved in cellular signaling, or by directing cell compartmentalization (Kay et al., 2000) . Another interesting features of the amino acid sequence indicate that HCCA1 protein may be phosphorylation-associated. Numerous phosphorylation sites indicate that HCCA1 protein might be regulated by kinases such as PKC, PKA, PKG, GSK3, p34cdc2, tyrosine kinases, CaMII, CK I and CK II. To explore the possibly biological function, we designed several antisense oligonucleotides in attempt to target the transcript inside the cells, showing that inhibition of HCCA1 expression in HuH-7 cells significantly suppressed the cell proliferation in a timeand dose-dependent manner. Strong evidence is that HCCA1 antisense expression in HuH-7 cells resulted in a significant reduction in colony formation efficiency. Furthermore, the HCCA1 antisense expressed HuH-7 cells produced smaller colony size than that in vector control. It is deemed that a gene, such as HCCA1, involved in regulation of cell growth and differentiation in a positive fashion, might promote neoplastic development. Together with its distinct primary structure features and a subcellular localization in cytoplasm, HCCA1 might be activated in the intracellular signal cascades. Total activation of HCCA1 in HCC might result in uncontrollable cell growth, and thus possibly involves in this disease carcinogenesis and progression.
In summary, we describe in this study the identification of a novel HCC-associated cytoplasmic protein HCCA1, which is up-regulated frequently in advanced HCCs. HCCA1 is a growth-promoting protein that might be involved in HCC metastatic progression, and it will be a novel useful marker for HCC and a potential target for pharmaceutical intervention in this malignant disease.
Materials and methods
Subjects
This retrospective study encompassed 102 chinese patients (82 men and 20 women; range, 24 -74 years; mean, 45.6 years) with HCC surgically resected in our hospital from 1998 -1999. Histopathologic analysis was independently performed by two pathologists without awareness of the clinical data. Tumor-cell differentiation was graded as I, II, III, or IV (when heterogenous, the predominant grade was assigned) according to a modification of the Edmondson Grading System as described (Edmondson and Steiner, 1954; Kenmochi et al., 1987) , and capsular formation and regional spread (vascular invasion and metastasis) of tumor were assessed as depicted by Takayama et al. (1998) . Satellite nodules are daughter tumors with a distinct distance from their primary mother tumor. The tumor thrombus in portal vein was evaluated by macrography combined with microscopic examination. Out of the 102 liver-resected specimens, 72 (70.6%) cases displayed cirrhosis. 36 HCCs had integrity of fibrocapsule without intrahepatic metastasis, whereas among the other 66 HCCs with broken fibrocapsule, 43 tumors had satellite nodules and 28 tumors had portal thrombus. Positive anti-HbsAg in serum was detected in 80 out of 102 (78.4%) patients and positive serologic anti-HCV was found in 10 out of 48 (20.8%) cases examined. An elevated serologic AFP level (425 mg/l) was detected in 61 out of 102 (59.6%) cases and a much higher level (41000 mg/l) in 35 cases. A number of normal human tissues and various malignant tumors were also used to examine the distribution and specificity of the identified cDNA as described below.
Cell lines and cell culture
A number of cell lines (ATCC, Rockville, MD, USA) were included in this study. These were HepG2 (ATCC HB-8065), HuH-7, SK-Hep-1 (ATCC HTB-52), Chang liver (ATCC CCL-13), NCI-H1755 (ATCC CRL-5892, Gazdar A and Minna J), Ts817t (ATCC CRL-7549), WRL 68 (ATCC CL-48) and a human embryonic kidney fibroblast 293 cell line (HEK293). All cells were cultured in DMEM supplemented with 10% fetal bovine serum at 378C in 5% CO 2 .
Differential display, HCCA1 cDNA cloning and sequencing
Differential display was performed as described by Liang et al. (1993) . Briefly, 2 mg of total RNA extracted from HCC tissues or paired nontumorous tissues served as a template to synthesize the first strand cDNA primed by a 13-mer anchored oligo(dT) primer (dT 11 MC). After reverse transcription, PCR was performed using the same anchored primer and an arbitrary 10-base olignucleotide A2 (5'-AATCGGGCTG-3'). For subsequent visualization of the amplification products by autoradiography, 10 mCi of a-32 PdATP (Amersham Pharmacia Biotech) was included in the PCR reactions. Amplification consisted of initial denaturation at 948C for 5 min, followed by 35 reaction cycles (30 s at 948C, 2 min at 608C, and 30 s at 728C) and a final cycle at 728C for 8 min. The PCR products were fractionated by electrophoresis on a 6% nondenaturing sequencing gel and then subjected to autoradiography. Bands exclusively present in either two samples were considered as candidates of differentially expressed transcripts, which were excised, eluted, reamplified and subcloned into the pGEM-T easy vector (Promega, Madison, WI, USA). A human placental cDNA library was screened using the cloned PCR fragment as probe to isolate the full-length cDNA for HCCA1 and positive clones from this library were identified by Southern blot as in our previous description (Wang et al., 1996) . The identified cDNA clones were sequenced using an automated sequencing system (Model 3700, PE Biosystems, USA). The 5'-end sequence of the identified gene was determined by 5'-RACE using a 5'-RACE kit (Clontech Laboratories, Palo Alto, CA, USA) according to the manufacturer's instruction. The sequence data were analysed with ExPASy (Expert Protein Analysis System) proteomics tools using ExPASy molecular biology server (http://www.expasy.ch/). Sequence homology to published database was analysed with the BLAST program at an internet site of NCBI (National Center for Biotechnology Information) (http:// www.ncbi.nlm.nih.gov/blast/blast.cgi).
Bacterial expression, purification and polyantibody preparation
A cDNA fragment (nt 320 to 841) coding for the HCCA1 N-terminal 174 amino acids was generated by PCR and inserted into EcoRI/XhoI sites of pGEX-5-X-1 vector. The new plasmid, pHCCA1-N174, was sequenced to check for mutations and used to transform BL-21 Escherichia coli. BL-21 cells containing pHCCA1-N174 were then cultured in LB medium at 378C and induced with 1 mM isopropyl-b-Dthiogalactopyranoside at A 600 =0.7 for 4 h. The cultures were harvested and lysed for 30 min in ice-cold TS buffer containing 50 mM Tri-HCl (pH 8.0), 150 mM NaCl, 1 mg/ml lysozyme, 5 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, and 0.2 mg/l aprotinin. The lysates were sonicated (at 80% intensity and 0.5 frequency) three times, 1-min burst and 1-minute cooling each, and treated with 1% Triton X-100 on ice for 15 min. After centrifugation at 15 000 r.p.m. for 1 h, the supernatant was mixed with 2 ml glutathione-sepharose 4B for 2 h at 48C. The slurry was loaded into a column, washed extensively with PBS buffer and eluted with a buffer containing 50 mM Tris-HCl (pH 8.0), 1 mM DTT, and 10 mM glutathione. The samples containing purified HCCA1-GST fusion protein were examined by electrophoresis on 8% SDS -PAGE gel and stored in aliquots at 7808C. For preparation of polyantibody, 2 mg of the purified HCCA1-GST fusion protein were emulsified with complete Freund's adjuvant (Gibco BRL, Life Technologies) and subcutaneously injected into two New Zealand rabbits. Following the first immunization, 1 mg, 0.5 mg and 0.25 mg was used to re-immunize the rabbits at two week intervals. Antibody valence was determined by double immunodiffusion test on 1% agar gel and the specificity was confirmed by Western blotting. The antibody was affinity purified using the antigenic peptide-conjugated Affi-Gel 15 (Bio-Rad) according to the manufacturer's instructions.
Eukaryotic expression and immunocharacterization
The full-length cDNA of HCCA1 was released from pBluescript SK and subcloned into EcoRI/XhoI sites of pcDNA3 vector. The recombinant was used to transfect human embryonic kidney fibroblast 293 cells (HEK293) for overexpression of the HCCA1 protein. HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 10 mM HEPES, penicillin (50 units/ml), and streptomycin (50 mg/ml) at 378C in 5% CO 2 . At 50% confluency, the cells were transfected with 2 mg HCCA1/pcDNA3 plasmid or the mock vector as control using FuGENE TM 6 transfection reagent (Boehringer Mannheim) according to the manufacturer's instruction. Thirty hours after transfection, the cells were washed with ice-cold phosphate-buffered saline and lysed in a buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 10mM sodium pyrophosphate, 40 mM sodium orthovanadate, 1 mg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 10% glycerol and 1% Triton X-100 on ice for 20 min. The lysates were centrifugated at 10 000 r.p.m. for 1 min. The supernatant was separated on a 8% SDS -PAGE gel and transferred to nitrocellulose for hybridization with HCCA1 antibodies. ECL was used for detection of signals (Amersham Life Science). Endogenous expression of HCCA1 protein was also examined in HuH-7 cell lines by Western blot analysis in the same way. The subcellular localization of HCCA1 protein was determined by immunohistochemistry as described below.
Antisense assay
Antisense technology was employed in this study (Liao et al., 2000) . Antisense sequence against the whole ORF of HCCA1 was generated by PCR and inserted into pcDNA3 vector between EcoRI and XhoI sites (AS-HCCA1/pcDNA3). Various oligodeoxynucleotides (ODNs) including antisense (AS), sense (S) and random (R) were phosphorothioate oligodeoxynucleotides synthesized at Gene Co. Ltd., which are shown below: AS1: 5'-CCATGTTGGAGAATCCCATC-TC-3'; S1: 5'-GAGATGGGATTCTCCAACATGG-3'; AS2: 5'-TGGCTGTATTGGGTGAGGAATC-3'; S2: 5'-GATTCC-TCACCCAATACAGCCA-3'; AS3: 5'-GGGGTGGATGG-TATAGGAAGAT-3'; S3: 5'-ATCTTCCTATACCATCCAC-CCC-3'; R: 5'-TCATGTACTGTCTGTAATGAGTTG-3'.
Antisense assay was performed on one HCC cell line (HuH-7). Briefly, HuH-7 cells were seeded in a 96-well plate at low cell density (*200 cells/well) and allowed to attach overnight. The cells were then treated with various concentrations of ODNs (0, 100, 500, 1000, 1500 nM) over periods arranging from 12 -48 h to check the efficacy of growth inhibition, and some cells were allowed another 24-h incubation to evaluate the turnover of the inhibited cells. Viable cells were counted by standard MTT assay (Miyake et al., 2000) at indicated time and were expressed as relative cell viability by normalization to control (ODNs=0 nM was used as control). Effects of AS-ODNs treatment on HCCA1 expression were confirmed by Northern blot analysis. For the clonogenic assay, HuH-7 cells were seeded at a density of 2610 5 cells/well in 60-mm plates and allowed to attach overnight. At 70% confluency, the cells were cotransfected with 1 mg of pCMV-bGAL and either 2 mg of pcDNA3 that included antisense HCCA1 or 2 mg of empty vector using FuGENE TM 6 transfection reagent as described above. Forty-eight hours after transfection, harvested cells were split 1 : 4 into 100-mm plates: two plates were cultured in DMEM with 10% calf serum for measuring transfection efficiency and the others were selected with 600 mg/ml G418 (Life Technologies, Inc.) in the same medium for focus formation assays. Cell lysates of the transfected cells were prepared 36 h after splitting and monitored for b-galactosidase activity against the substrate o-nitrophenyl-b-Dgalactopyranoside (Sigma) by colorimetric assay at A 420 in a spectrophotometer as described by Bouchier-Hayes et al (2001) . Antibiotic selection was continued for three weeks. Colonies were fixed with 2% formaldehyde in PBS and stained with 0.4% crystal violet in 20% ethanol. Colonies larger than 60 mm in diameter were counted with an image analyzer (Omnicon) and colony number for vector alone was normalized to 100%. Each transfection experiment was performed in triplicate and repeated five times.
Northern blot analysis
Total RNAs were prepared from various cells and tissues according to the standard guanidinium thiocyanate-phenolchloroform method (Chomczynski and Sacchi, 1987) and kept at 7708C until used. Forty mg of total RNAs were separated on a 1% formaldehyde/agarose gel by electropherosis, transferred to nitrocellulose and hybridized with a-32 P-labeled full-length cDNA for HCCA1. The expression level of mRNA for HCCA1 was normalized with 18S rRNA as internal standard and analysed by Phosphor imager (FLA 2000, Fujifilm, Japan).
In situ hybridization
Antisense cRNA probe for HCCA1 was transcribed with T7 RNA polymerase using a digoxigenin labeling kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's protocol. A sense probe for HCCA1 transcribed with SP6 RNA polymerase served as control. HCC surgical specimens fixed in 4% paraformaldehyde were embedded in paraffin and five-micrometer paraffin sections were subjected to an in situ hybridization (ISH) test. Briefly, the rehydrated sections were rinsed in 0.1 M PBS, pH 7.2, and treated with 0.1 M glycine and 0.4% Triton X-100. They were then digested with 1 mg/ml proteinase K at 378C, and 20 min later, the proteinase K activity was stopped by postfixation with 4% paraformaldehyde. Sections were washed in 0.1 M PBS, pH 7.2, and acetylated for 10 min in 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0). After equilibration in 56SSC for 15 min, they were prehybridized for 4 h at 438C in a solution containing 50% formamide, 10% dextran sulfate, 106Denhardt's solution, 10 mM TrisHCl (pH 8.0), 300 mM NaCl, 1 mM EDTA and 250 mg/ml E. coli transfer RNA. Sections were hybridized with the probes (0.5 mg/ml) in the same buffer at 438C for 16 h. After hybridization, they were washed twice in 26SSC at room temperature for 20 min and digested with ribonuclease A (10 mg/ml) at 378C for 30 min. They were further rinsed twice in 0.56SSC and twice in 0.05 M PBS, pH 7.2. Sections were incubated in a buffer containing 0.1 M maleic acid and 0.15 M NaCl, pH 7.5, and blocked with 1% blocking reagent at room temperature for 2 h. Immunologic detection was performed using alkaline phosphatase-coupled antidigoxigenin antibody at a dilution of 1 : 5000 at room temperature for 4 h. Sections were washed twice in 0.05 M PBS, pH 7.4, for 10 min, and equilibrated in TSM1 buffer containing 100 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 10 mM MgCl 2 and then in TSM2 buffer containing 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, and 50 mM MgCl 2 . The color reaction was developed in TSM2 buffer plus 0.2 mg/ml BCIP and 0.4 mg/ml NBT (provided with DIG nucleic acid detection kit, Roche Molecular Biochemicals) and examined under a light microscope. In the same way, different HCCrelated cell lines and the fetal hepatic cell line (WRL68) were also subjected to ISH.
Immunohistochemistry
Surgical specimens including HCC tissues and paracarcinoma liver tissues were fixed in 10% neutral formalin, dehydrated in graded alcohol and embedded in paraffin. Five-micrometer paraffin sections were subjected to immunoperoxidase staining with HCCA1 antibody using immunopure staining ABC kit (Pierce) according to the manufacturer's instruction. Briefly, after deparaffination with xylene and rehydration in ethanol gradient, sections were incubated in 3% H 2 O 2 to block endogenous peroxidase. The sections were then incubated with 10% goat serum to reduce nonspecific binding. Afterwards, the sections were sequentially incubated with affinity-purified anti-HCCA1 antibody, biotinylated goat anti-rabbit IgG and avidin-biotin complex. Control sections were incubated with preimmune serum from the rabbit in the same way. The sections were incubated with 3,3'-diaminobenzidine tetrahydrochloride in 0.03% H 2 O 2 and 50 mM Tris-HCl (pH 7.4) for detection. Finally, the sections were counterstained with Harris's hematoxylin and examined under a light microscope. To assess the specificity, competitive inhibition experiments was performed by preabsorption of the antisera with excess purified recombinant HCCA1-GST or GST peptide for 6 h at room temperature, and omission of the primary antibody was used as control to determine the amount of background generated from the detection assay. HCCA1 protein expression in HuH-7 cells was similarly analysed. HCC sections were also subjected to examine Ki-67 expression using Ki-67 antibody (Immunotech, SA, Marseilles, France) in the same way.
Statistical analysis
Statistical analyses were performed with Statview 5.0 (SAS Institute, Inc, Cary, NC, USA). Significance was determined by ANOVA with Fisher's protected least significant difference. Values were considered statistically significant at P50.05.
